evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 2 · 33.3%High 2 · 33.3%

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

All‐cause mortality (RR) Range of · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).

1 finding from 1 review

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

All‐cause mortality · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor blockers (ARBs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (high certainty).

1 finding from 1 review